skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Modeling HCV cure after an ultra-short duration of therapy with direct acting agents

Abstract

In cases of sustained-virological response (SVR or cure) after an ultra-short duration (≤ 27 days) of direct-acting antiviral (DAA)-based therapy, despite HCV being detected at end of treatment (EOT), have been reported. Established HCV mathematical models that predict the treatment duration required to achieve cure do not take into account the possibility that the infectivity of virus produced during treatment might be reduced. The aim of this study was to develop a new mathematical model that considers the fundamental and critical concept that HCV RNA in serum represents both infectious virus (Vi) and non-infectious virus (Vni) in order to explain the observation of cure with ultrashort DAA therapy. Established HCV models were compared to the new mathematical model to retrospectively explain cure in 2 patients who achieved cure after 24 or 27 days of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin or sofosbuvir plus ribavirin, respectively. Fitting established models with measured longitudinal HCV viral loads indicated that in both cases, cure would not have been expected without an additional 3–6 weeks of therapy after the actual EOT. In contrast, the new model fits the observed outcome by considering that in addition to blocking Vi and Vni production (ε~0.998), these DAA +more » ribavirin treatments further enhanced the ratio of Vni to Vi, thus increasing the log (Vni/Vi) from 1 at pretreatment to 6 by EOT, which led to <1 infectious-virus particle in the extracellular body fluid (i.e., cure) prior to EOT. This new model can explain cure after short duration of DAA + ribavirin therapy by suggesting that a minimum 6-fold increase of log (Vni/Vi) results from drug-induced enhancement of the Vni/Vi.« less

Authors:
 [1];  [2];  [3];  [4];  [5];  [5];  [6];  [6]
  1. Loyola Univ. Medical Center, Maywood, IL (United States). Program for Experimental and Theoretical Modeling; Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
  2. Sha'are Zedek Medical Center, Jerusalem (Israel)
  3. Medical Univ. of South Carolina, Charleston, SC (United States). Dept. of Microbiology and Immunology; National Inst. of Health (NIH), Bethesda, MD (United States). national Inst. of Allergy and Infectious Diseases
  4. Food and Drug Administration, Silver Springs, MD (United States). Center for Biologics Evaluation and Research
  5. Loyola Univ. Medical Center, Maywood, IL (United States). Program for Experimental and Theoretical Modeling; Univ. of Illinois, Chicago, IL (United States). Dept. of Microbiology and Immunology
  6. Loyola Univ. Medical Center, Maywood, IL (United States). Program for Experimental and Theoretical Modeling
Publication Date:
Research Org.:
Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
USDOE; National Institutes of Health (NIH)
OSTI Identifier:
1375871
Report Number(s):
LA-UR-17-20262
Journal ID: ISSN 0166-3542
Grant/Contract Number:  
AC52-06NA25396
Resource Type:
Accepted Manuscript
Journal Name:
Antiviral Research
Additional Journal Information:
Journal Volume: 144; Journal Issue: C; Journal ID: ISSN 0166-3542
Publisher:
Elsevier
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES; Biological Science

Citation Formats

Goyal, Ashish, Lurie, Yoav, Meissner, Eric G., Major, Marian, Sansone, Natasha, Uprichard, Susan L., Cotler, Scott J., and Dahari, Harel. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. United States: N. p., 2017. Web. https://doi.org/10.1016/j.antiviral.2017.06.019.
Goyal, Ashish, Lurie, Yoav, Meissner, Eric G., Major, Marian, Sansone, Natasha, Uprichard, Susan L., Cotler, Scott J., & Dahari, Harel. Modeling HCV cure after an ultra-short duration of therapy with direct acting agents. United States. https://doi.org/10.1016/j.antiviral.2017.06.019
Goyal, Ashish, Lurie, Yoav, Meissner, Eric G., Major, Marian, Sansone, Natasha, Uprichard, Susan L., Cotler, Scott J., and Dahari, Harel. Fri . "Modeling HCV cure after an ultra-short duration of therapy with direct acting agents". United States. https://doi.org/10.1016/j.antiviral.2017.06.019. https://www.osti.gov/servlets/purl/1375871.
@article{osti_1375871,
title = {Modeling HCV cure after an ultra-short duration of therapy with direct acting agents},
author = {Goyal, Ashish and Lurie, Yoav and Meissner, Eric G. and Major, Marian and Sansone, Natasha and Uprichard, Susan L. and Cotler, Scott J. and Dahari, Harel},
abstractNote = {In cases of sustained-virological response (SVR or cure) after an ultra-short duration (≤ 27 days) of direct-acting antiviral (DAA)-based therapy, despite HCV being detected at end of treatment (EOT), have been reported. Established HCV mathematical models that predict the treatment duration required to achieve cure do not take into account the possibility that the infectivity of virus produced during treatment might be reduced. The aim of this study was to develop a new mathematical model that considers the fundamental and critical concept that HCV RNA in serum represents both infectious virus (Vi) and non-infectious virus (Vni) in order to explain the observation of cure with ultrashort DAA therapy. Established HCV models were compared to the new mathematical model to retrospectively explain cure in 2 patients who achieved cure after 24 or 27 days of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin or sofosbuvir plus ribavirin, respectively. Fitting established models with measured longitudinal HCV viral loads indicated that in both cases, cure would not have been expected without an additional 3–6 weeks of therapy after the actual EOT. In contrast, the new model fits the observed outcome by considering that in addition to blocking Vi and Vni production (ε~0.998), these DAA + ribavirin treatments further enhanced the ratio of Vni to Vi, thus increasing the log (Vni/Vi) from 1 at pretreatment to 6 by EOT, which led to <1 infectious-virus particle in the extracellular body fluid (i.e., cure) prior to EOT. This new model can explain cure after short duration of DAA + ribavirin therapy by suggesting that a minimum 6-fold increase of log (Vni/Vi) results from drug-induced enhancement of the Vni/Vi.},
doi = {10.1016/j.antiviral.2017.06.019},
journal = {Antiviral Research},
number = C,
volume = 144,
place = {United States},
year = {2017},
month = {6}
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record

Citation Metrics:
Cited by: 4 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

Post-treatment control of HIV infection
journal, April 2015

  • Conway, Jessica M.; Perelson, Alan S.
  • Proceedings of the National Academy of Sciences, Vol. 112, Issue 17
  • DOI: 10.1073/pnas.1419162112

HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
journal, June 2016


Triphasic decline of hepatitis C virus RNA during antiviral therapy
journal, January 2007

  • Dahari, Harel; Ribeiro, Ruy M.; Perelson, Alan S.
  • Hepatology, Vol. 46, Issue 1
  • DOI: 10.1002/hep.21657

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection
journal, December 2004

  • Dixit, Narendra M.; Layden-Almer, Jennifer E.; Layden, Thomas J.
  • Nature, Vol. 432, Issue 7019
  • DOI: 10.1038/nature03153

Development of a TaqMan assay for the six major genotypes of hepatitis C virus: Comparison with commercial assays
journal, January 2007

  • Engle, Ronald E.; Russell, Rodney S.; Purcell, Robert H.
  • Journal of Medical Virology, Vol. 80, Issue 1
  • DOI: 10.1002/jmv.21043

Non-A, Non-B Hepatitis in Chimpanzees and Marmosets
journal, December 1981

  • Feinstone, S. M.; Alter, H. J.; Dienes, H. P.
  • Journal of Infectious Diseases, Vol. 144, Issue 6
  • DOI: 10.1093/infdis/144.6.588

Modeling Early HCV Kinetics to Individualize Direct Acting Antivirals Treatment Duration in Patients with Advanced Cirrhosis
journal, January 2016


Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
journal, February 2013

  • Guedj, J.; Dahari, H.; Rong, L.
  • Proceedings of the National Academy of Sciences, Vol. 110, Issue 10
  • DOI: 10.1073/pnas.1203110110

Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report
journal, January 2016

  • Hasin, Yaakov; Shteingart, Shimon; Dahari, Harel
  • World Journal of Hepatology, Vol. 8, Issue 20
  • DOI: 10.4254/wjh.v8.i20.858

Mutagenic Effect of Ribavirin on Hepatitis C Nonstructural 5B Quasispecies In Vitro and During Antiviral Therapy
journal, March 2007


Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
journal, May 2014

  • Kowdley, Kris V.; Gordon, Stuart C.; Reddy, K. Rajender
  • New England Journal of Medicine, Vol. 370, Issue 20
  • DOI: 10.1056/NEJMoa1402355

Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study
journal, October 2016


Visualizing Hepatitis C Virus Infections in Human Liver by Two-Photon Microscopy
journal, October 2009


Mutation Rate of the Hepatitis C Virus NS5B in Patients Undergoing Treatment With Ribavirin Monotherapy
journal, May 2007


Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge
journal, July 2002


Sustained Virologic Response for Chronic Hepatitis C Infection After 27 Days of Treatment with Sofosbuvir and Ribavirin
journal, January 2014

  • Meissner, Eric G.; Nelson, Amy; Marti, Miriam
  • Open Forum Infectious Diseases, Vol. 1, Issue 1
  • DOI: 10.1093/ofid/ofu013

No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL
journal, November 2015

  • O'Brien, Thomas R.; Feld, Jordan J.; Kottilil, Shyam
  • Hepatology, Vol. 63, Issue 1
  • DOI: 10.1002/hep.28292

A Comprehensive Hepatitis C Viral Kinetic Model Explaining Cure
journal, May 2010

  • Snoeck, E.; Chanu, P.; Lavielle, M.
  • Clinical Pharmacology & Therapeutics, Vol. 87, Issue 6
  • DOI: 10.1038/clpt.2010.35

Sporadic Reappearance of Minute Amounts of Hepatitis C Virus RNA After Successful Therapy Stimulates Cellular Immune Responses
journal, February 2011


    Works referencing / citing this record:

    Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis
    journal, December 2018

    • Gambato, Martina; Canini, Laetitia; Lens, Sabela
    • Liver International, Vol. 39, Issue 5
    • DOI: 10.1111/liv.14014

    Interferon at the cellular, individual, and population level in hepatitis C virus infection: Its role in the interferon-free treatment era
    journal, August 2018

    • Raja, Rubesh; Baral, Subhasish; Dixit, Narendra M.
    • Immunological Reviews, Vol. 285, Issue 1
    • DOI: 10.1111/imr.12689

    Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection
    journal, July 2018